咨詢熱線
15000266580
熱門關(guān)鍵詞：ATCC 細(xì)胞,細(xì)胞系,細(xì)胞株,腫瘤細(xì)胞,細(xì)胞,ATCC 菌種，CMCC 菌種，標(biāo)準(zhǔn)菌株，質(zhì)控菌種，微生物菌種，菌株，菌種
當(dāng)前位置：首頁 >產(chǎn)品中心>細(xì)胞系>人源細(xì)胞系>CRL-2547Panc 10.05細(xì)胞，人胰腺腺癌細(xì)胞
簡要描述：Panc 10.05細(xì)胞，人胰腺腺癌細(xì)胞原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻和*培養(yǎng)條件！
產(chǎn)品型號：CRL-2547廠商性質(zhì)：生產(chǎn)廠家 更新時間：2026-03-22訪 問 量：2215 產(chǎn)品分類
Product Category詳細(xì)介紹
Panc 10.05細(xì)胞，人胰腺腺癌細(xì)胞
| ATCC® Number: | CRL-2547™ | Price: | $338.00 |
| Dsafety Level:1Shipesignations:Panc 10.05Depositors:EM JaffeeBioped:frozenMedium & Serum:See PropagationGrowth Properties:adherentOrganism:Homo sapiens (human)Morphology:epithelial Source:Organ: pancreas Disease: adenocarcinomaCellular Products:cytokeratins 7 and 18 [50655]Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.Panc 10.05細(xì)胞，人胰腺腺癌細(xì)胞Isolation:Isolation date: 1992Tumorigenic:YesOncogene:K-ras +Antigen Expression:MHC class I +; MHC class II -DNA Profile (STR):Amelogenin: X CSF1PO: 12 D13S317: 12 D16S539: 9,12 D5S818: 13 D7S820: 8,9 THO1: 6,9.3 TPOX: 11 vWA: 16Age:*****Gender:maleEthnicity:WhiteComments:Panc 10.05 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma. Both the PL45 and the Panc 10.05 cell lines exhibit a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655] The cells have a reported plating efficiency of 40%. [50655] The Panc 10.05 cell line was derived from the same patient as the PL45 cell line (ATCC CRL-2558).Propagation:ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 10 Units/ml human insulin, 85%; fetal bovine serum, 15%Temperature: 37.0°CSubculturing:Protocol: Remove and discard culture medium.Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.Add appropriate aliquots of the cell suspension to new culture vessels.Incubate cultures at 37°C.Subc*tion Ratio: A subc*tion ratio of 1:2 to 1:4 is recommended Medium Renewal: Every 2 to 3 daysPreservation:Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phaseDoubling Time:19.2 hrsRelated Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001recommended serum:ATCC 30-2020derived from same individual:ATCC CRL-2558References:50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 | |||
產(chǎn)品咨詢
郵箱：xiangfbio@163.com
地址：上海市虹口區(qū)四平路710號7層
掃一掃 微信咨詢
